MPLT enters its August 14 print carrying the scars of a dramatic analyst reset — and the question heading into Thursday is whether the ZEPHYR Phase 2b data can reopen the bull case that was closed so abruptly two weeks ago.
The most telling development came on July 28, when Morgan Stanley downgraded MPLT to Equal-Weight from Overweight and cut its target from $34 to $21 — the kind of move from a bellwether firm that resets the Street's tone. The same day, Canaccord Genuity and HC Wainwright each slashed their targets by roughly 40% while holding Buy ratings. Then on August 10 — the day before this article — UBS downgraded from Buy to Neutral and cut from $52 to $13, landing within a dollar of the current price. The consensus target now averages around $32, but that figure reflects a mix of pre- and post-reset views; the most recent actions cluster near $13–$26. The stock itself has collapsed 69% over the past month to $12.18, making this analyst activity less a debate about valuation and more a reappraisal of clinical probability.
The bull and bear cases converge almost entirely on ML-007C-MA and the ZEPHYR schizophrenia trial. Bulls emphasize the drug's muscarinic agonist M1/M4 mechanism, a potentially differentiated once-daily profile, and additional readthrough potential from Bristol Myers Squibb's ADEPT study later this year. Bears point to discontinuation rates, PK variability in older patients, and what they see as overoptimistic peak sales assumptions — particularly if cognitive endpoints require further confirmation. The company is pre-revenue, with a price-to-book near 1.6x and deeply negative earnings multiples, so valuation provides no floor independent of clinical outcomes.
The insider data adds a notable counterpoint to the analyst pessimism. Catalyst4, the company's largest shareholder at 46% of shares, bought over $15 million worth of stock between July 28 and July 30 — stepping in aggressively at prices between $10.74 and $13.00 as the stock was falling hard. A director also bought in on July 28. That concentrated insider accumulation at the lows contrasts sharply with the analyst downgrades, and it is among the more decisive signals in the setup. Novo Holdings trimmed 1.6 million shares over the same period, partially offsetting the picture.
Short interest has pulled back from its recent peak but remains elevated at 8.7% of free float — up 81% over the past month before falling 16% this week. Availability tightened severely in early August, reaching near-zero on August 4, before loosening back to roughly 42% as short sellers covered. Borrowing costs nearly doubled over the past week to just under 2%, elevated for a biotech of this size but not extreme. Options positioning is mildly more defensive than usual — the put/call ratio at 0.54 sits slightly above its 20-day average — but the z-score of 0.57 suggests no dramatic hedging surge ahead of the print.
The August 14 earnings report is therefore less a financial update and more a verdict on whether ZEPHYR's data can rebuild a clinical thesis that Wall Street has spent the last two weeks dismantling.
See the live data behind this article on ORTEX.
Open MPLT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
